Table 1.

Details of infants included in previously published studies

Study	Characteristics of infants included and study
Author/year	Age criteria	Specific inclusion criteria	Data source/location	Study period
Hall et al. (2013) [12]	All children aged <24 months	Hospitalized for laboratory-confirmed RSV infection	New Vaccine Surveillance Network from Nashville, TN, Rochester, NY, and Cincinnati, OH	October 1, 2000 to March 31, 2001; October 1, 2001 to March 31, 2002; October 1, 2002 to March 31, 2003; October 1, 2003 to March 31, 2004; October 1, 2004 to March 31, 2005
Helfrich et al. (2015) [13]	Non-high-risk infants 33–36 wGA and term infants	No receipt of palivizumab	Military Health System	October 1, 2005 to April 30, 2011
Anderson et al. (2017) [14]	29–35 wGA	No RSV immunoprophylaxis received and hospitalized for laboratory-confirmed RSV infection	Data from 43 diverse US practices	October 1, 2014 to April 30, 2015

RSV respiratory syncytial virus, wGA weeks gestational age